cropped-transparent-01.png
Our focus

Challenges in the cardiological health care

34% of
mortalities

will be attributable to cardiovascular disease in 2020. This makes it the most common cause of death, with an additional upward trend.

6 million CHD patients

In Germany alone, there are around 6 million CHD patients. As a result, more than 240,000 patients are treated with a stent every year in Germany.

1.7 million full inpatient cases

are treated in a hospital each year in Germany for heart disease. Almost 218,000 of these were treated in a hospital for a heart attack.

34% of
mortalities

will be attributable to cardiovascular disease in 2020. This makes it the most common cause of death, with an additional upward trend.

6 million
CHD patients.

In Germany alone, there are around 6 million CHD patients. As a result, more than 240,000 patients are treated with a stent every year in Germany.

1.7 million
full inpatient cases

are treated in a hospital each year in Germany for heart disease. Almost 218,000 of these were treated in a hospital for a heart attack.

A strong connection

Cluster for Atherothrombosis and Individualized Medicine - curATime

The goal of the cluster is to develop tailored treatment and prevention concepts for cardiovascular diseases and their clinical application. Biomarker profiles and risk factors are identified by using individualized and subgroup-specific approaches. These will then be used to develop diagnostic, preventive and therapeutic approaches, including the development of new algorithms to improve therapy selection and risk assessment, as well as eHealth apps and smart devices. 

We strongly believe that CureCurve with eLina is an excellent extension of our cluster network and in doing so can make an important contribution to achieving our vision.

Dr. Andree Rothermel TRON Managing Director & curATime Cluster Speaker

We strongly believe that CureCurve with eLina is an excellent extension of our cluster network and in doing so can make an important contribution to achieving our vision.

Dr. Andree Rothermel TRON Managing Director & curATime Cluster Speaker

Valued partners

More Projects In Progress

Together with selected partners we want to achieve our common goals! Join our network and become our comrade-in-arms.

Contact Form Demo